{"id":4837,"date":"2024-08-26T11:12:13","date_gmt":"2024-08-26T09:12:13","guid":{"rendered":"https:\/\/studienportal-brustkrebs.de\/breast-cancer-study-showed-improved-progression-free-survival-in-advanced-hr-her2-breast-cancer\/"},"modified":"2025-07-31T00:46:26","modified_gmt":"2025-07-30T22:46:26","slug":"breast-cancer-study-showed-improved-progression-free-survival-in-advanced-hr-her2-breast-cancer","status":"publish","type":"post","link":"https:\/\/studienportal-brustkrebs.de\/en\/breast-cancer-study-showed-improved-progression-free-survival-in-advanced-hr-her2-breast-cancer\/","title":{"rendered":"Breast Cancer Study Showed Improved Progression-Free Survival in Advanced HR+, HER2- Breast Cancer"},"content":{"rendered":"

 <\/p>\n

You are currently viewing a placeholder content from Default<\/strong>. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.<\/p>

Unblock content<\/a> Accept required service and unblock content<\/a> <\/div> More Information<\/a> <\/div><\/div><\/div>\n

Breast Cancer Study Showed Improved Progression-Free Survival in Advanced HR+, HER2- Breast Cancer<\/strong><\/h2>\n

A new Phase III breast cancer study, led by Dr. K\u00fcmmel, shows promising results for the treatment of advanced HR+, HER2- breast cancer. The so-called postMONARCH study<\/strong> is the first of its kind to investigate the benefit of \u201ctreatment beyond progression\u201d with CDK4\/6 inhibitors. Patients whose disease had progressed despite prior therapy with CDK4\/6 inhibitors and endocrine therapy benefited from continued treatment with abemaciclib. The study recorded a 27% risk reduction for disease progression and demonstrated a significant improvement in progression-free survival (PFS)<\/p>\n

Study Design and Results<\/strong><\/p>\n

Study Lead:<\/strong> Dr. K\u00fcmmel<\/p>\n

Design:<\/strong> Randomized, placebo-controlled Phase III study<\/p>\n

Treatment:<\/strong> Abemaciclib<\/p>\n

Results:<\/strong><\/p>\n

    \n
  1. Abemaciclib<\/em> showed a significant improvement in progression-free survival (PFS).<\/li>\n
  2. There was a 27% risk reduction for disease progression.<\/li>\n
  3. The control arm performed better than expected, but the results confirmed the benefit of continued CDK4\/6 inhibitor therapy.<\/li>\n<\/ol>\n

    This study shows for the first time that continued treatment with CDK4\/6 inhibitors after disease progression can be beneficial.<\/p>\n","protected":false},"excerpt":{"rendered":"

      Breast Cancer Study Showed Improved Progression-Free Survival in Advanced HR+, HER2- Breast Cancer A new Phase III breast cancer study, led by Dr. K\u00fcmmel, shows promising results for the treatment of advanced HR+, HER2- breast cancer. The so-called postMONARCH study is the first of its kind to investigate the benefit of \u201ctreatment beyond progression\u201d […]<\/p>\n","protected":false},"author":2,"featured_media":5067,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[52],"tags":[],"class_list":["post-4837","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/posts\/4837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/comments?post=4837"}],"version-history":[{"count":1,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/posts\/4837\/revisions"}],"predecessor-version":[{"id":4962,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/posts\/4837\/revisions\/4962"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/media\/5067"}],"wp:attachment":[{"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/media?parent=4837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/categories?post=4837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/tags?post=4837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}